St. Jude Researchers Identified Neuroblastoma Gene Signature
A new study reveals a gene signature that helps scientists better distinguish malignant mesenchymal cells in neuroblastoma.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Should medical research institutions prioritize sharing new study models to help other scientists develop treatments?
Researchers at St. Jude Children's Research Hospital have identified a specific gene signature that distinguishes malignant mesenchymal cells in neuroblastoma. This advancement allows for more effective identification of these cells, which are known to be associated with treatment resistance.
Why it matters
Directly identifying these malignant cells was historically difficult because they are frequently mistaken for healthy mesenchymal cells. By improving detection, this discovery provides a path to better understand vulnerabilities and evaluate potential treatment strategies for patients.
The study utilized a cohort of 54 tumors collected from 50 patients. These findings build on a medical landscape where neuroblastoma five-year survival rates reach 95% for most patients but fall to 60% for the high-risk subset.
The players
St. Jude Children's Research Hospital
This Memphis-based pediatric treatment and research facility focuses on catastrophic diseases in children.
Cancer Cell
This peer-reviewed medical journal publishes significant research in the field of oncology and cell biology.
The details
The research team used single-cell RNA sequencing, spatial omics, and organoid models to pinpoint the signature, which distinguishes between malignant mesenchymal and adrenergic cells based on their unique cellular shapes. To validate the findings, investigators applied spatial proteomics, electron microscopy, and chromatin profiling while utilizing xenografted tumor cells.
Timeline
The study was published in the journal Cancer Cell in October 2026.
Health Landscape
This study leverages the St. Jude Childhood Solid Tumor Network to validate new genomic findings using complex, laboratory-grown tumor models. The work represents a significant milestone in characterizing the cellular heterogeneity that contributes to treatment resistance in childhood cancers.
While this discovery is currently laboratory-based, it provides a new foundation for developing targeted therapies that may eventually improve outcomes for high-risk patients. These advancements aim to address treatment resistance, which remains a primary challenge for clinicians treating pediatric neuroblastoma.
The takeaway
Identifying the specific gene signature of malignant mesenchymal cells helps researchers better understand why some neuroblastomas resist conventional treatment. Scientists are now using newly released in vitro models to test whether these signatures reveal new vulnerabilities that can be targeted by future medicine.
Further reading
For more on ongoing research into malignant tumors, visit the Cancer section.
Source note: This article includes information reported by Inside Precision Medicine.
Live Poll
Should medical research institutions prioritize sharing new study models to help other scientists develop treatments?
